早期非小细胞肺癌SBRT 201803培训班.ppt

山 东 省 肿 瘤 医 院 山东省肿瘤防治研究院 争议与展望 ? 2 项入组失败的 pooled analysis ? 随访时间短（ SABR 组 40.2 月 / 手术组 35.4 月） 均未达到中位总生存 ? 手术组不良反应高 ? SABR 组 8 例（ 26% ）无病理诊断，手术组 6 例（ 22% ）术前无病理（ 1 例手术良性） Ongoing trails ? RTOG 3502 ? VALOR ? SABRTooth RTOG Foundation 3502 POSTILV : A Randomized Trial in P atients with O perable St age I Non-Small Cell L ung Cancer: Radical Resection V s Ablative Stereotactic Radiotherapy Study Team Radiation oncologist PIs: J Yu (L Xing); FM Kong Surgeon Co- Chairs: Y Wu/J He/W Mao/G Chen; A Chang/M Orringer/T DAmico Radiation Co-Chairs: L Wang/X Fu; Z Liao/J Chang Physicist PIs: J Dai/Y Yin; F Yin/Y Xiao/J Yue … First 5 selected participating Sites Schema of RTOG Foundation Study 3502 Phase II Randomized Study Arm A R0 resection with Nodal Dissection/Sampling (RODS) Arm B Stereotactic Body Radiation Therapy (SBRT) R A N D O M I Z E R E G I S T E R Patients with pathology proven medically operable CT-staged T1N0 NSCLC Follow-up If fails, salvage treatment by surgery or radiation or systemic therapy. PET to confirm T1N0 disease Primary Endpoint: 2 year local regional tumor control, freedom from local-regional recurrence after RODS and freedom from progression of local primary tumor and disease occurrence at nodal regions after SBRT. 早期非小细胞肺癌 SBRT 复发后的挽救性治疗 Salvaging Local-Regional Recurrence after Stereotactic Ablative Radiotherapy (SABR) for Early-Stage NSCLC Presented By Eric Brooks at 2017 ASCO Annual Meeting Methods Presented By Eric Brooks at 2017 ASCO Annual Meeting Slide 18 Presented By Eric Brooks at 2017 ASCO Annual Meeting Slide 29 Presented By Eric Brooks at 2017 ASCO Annual Meeting Benefit of Salvage Treatment Presented By Eric Brooks at 2017 ASCO Annual Meeting Effect of Salvage on Survival Presented By Eric Brooks at 2017 ASCO Annual Meeting Slide 48 Presented By Eric Brooks at 2017 ASCO Annual Meeting Slide 56